Clinical trials: Cardiovascular Risk
STEMI, NSTEMI
Assessment of Individual Risk of Cardiovascular Events by Platelet FcGammaRIIa
This is a Prospective, Observational Multicenter Non-Interventional Cohort Study. The primary objective is to determine whether platelet expression of FcγRIIa is associated with risk of myocardial infarction (MI), stroke and…
- Trial name
- NCT05175261
- Testing
- Prolocor pFCG test
- Where
- United States
- Volunteers
- 764 people
- Sponsor
- Prolocor, Inc
Hypertrophic Cardiomyopathy, Sudden Cardiac Death
PRecIsion Medicine in CardiomyopathY
This is a retrospective cohort study of pediatric hypertrophic cardiomyopathy (HCM) patients using chart and registry review methodology.
- Trial name
- PRIMaCY (NCT04036799)
- Volunteers
- 572 people
- Sponsor
- The Hospital for Sick Children
Peripheral Artery Disease
Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities
The purpose of study was to test whether rivaroxaban added to standard of care treatment, when compared to placebo, had the potential to reduce the incidence of the clinical events related to the clots and complications of the…
- Trial name
- VOYAGER PAD (NCT02504216)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939)
- Where
- 532 sites in United States, Argentina and 32 more
- Volunteers
- 6,564 people
- Sponsor
- Bayer
Hypercholesterolaemia
Usability Study of the Commercial Auto-injector Device and the New Auto-injector Device (SYDNEY) in Patients With High or Very High CV Risk With Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy
Primary Objective: To collect real-use (usability) data assessing the robustness and user interaction of the new alirocumab auto-injector device (which is referred to as SYDNEY), in unsupervised settings.
- Trial name
- NCT03415178
- Testing
- Alirocumab SAR236553, Current auto-injector device (AI), New auto-injector device (SYDNEY)
- Where
- 13 sites in United States
- Volunteers
- 69 people
- Sponsor
- Sanofi
Myocardial Infarction
Risk Stratification in Patients With Preserved Ejection Fraction
The purpose of the study is to assess the prevalence and the prognostic value of non-invasive indexes and programmed ventricular stimulation for sudden cardiac death in post-myocardial infarction (MI) patients with left…
- Trial name
- PRESERVE-EF (NCT02124018)
- Testing
- Programmed ventricular stimulation, ICD implantation
- Where
- Greece
- Volunteers
- 575 people
- Sponsor
- University of Athens
Hypertension
Screen-and-treat Program for Chronic Kidney Disease- High Risk Persons
The overall hypothesis of this trial is that screening for chronic kidney disease, followed by education or treatment program will improve blood pressure control among hypertensive non-diabetic persons.
- Trial name
- NCT02059408
- Testing
- Screen-Educate, Screen-Educate and Intensify Treatment
- Where
- United States
- Volunteers
- 1,819 people
- Sponsor
- University of California, San Francisco
Diabetes Mellitus, Cardiovascular Diseases
Dissemination of CVD Risk Factor Treatment Among Diabetic Patients in Safety Net Clinics
The purpose of the ALL Study is to determine the effectiveness of the dissemination of the ALL intervention from an integrated care setting into Community Health Centers (CHCs) by measuring changes in diabetes mellitus (DM)…
- Trial name
- ALL (NCT02299791)
- Testing
- ALL
- Volunteers
- 4,856 people
- Sponsor
- Kaiser Permanente
Heart Diseases
A Partnership to Translate an Evidence-based Intervention (Take Heart) for Vulnerable Older Adults With Heart Disease
To evaluate the effectiveness of Take Heart, a behavioral/educational program for adults age 50+ with heart disease, or with at least two risk factors for heart disease, that helps them to better manage their health condition(s).
- Trial name
- NCT02950818
- Testing
- Take Heart
- Where
- United States
- Volunteers
- 453 people
- Sponsor
- University of Michigan
Chest Pain, Acute Coronary Syndrome
Computed Tomography Coronary Angiogram (CTCA) Versus Traditional Care in Emergency Department Assessment of Potential Acute Coronary Syndromes (ACS)
This multi-center, randomized, controlled trial conducted in Emergency Departments (ED) compares computed tomography (CT) coronary angiography with the traditional approach (usual care) for low- to intermediate-risk chest pain…
- Conditions
- Chest Pain, Acute Coronary Syndrome, Acute Myocardial Infarction, Coronary Artery Disease
- Trial name
- NCT00933400
- Testing
- CT Coronary Angiography (CTCA), Traditional Strategy
- Where
- 5 sites in United States
- Volunteers
- 1,392 people
- Sponsor
- American College of Radiology
Nutritional and Metabolic Diseases, Inflammation
A Study of Strawberries and Disease Risk
The purpose of this study is to test whether compounds found in strawberries (polyphenolics which are typically found in berry products, tea, coffee, red wine, and chocolate) will help reduce insulin resistance and inflammation…
- Conditions
- Nutritional and Metabolic Diseases, Inflammation, Physiological Responses
- Trial name
- STRB (NCT01199848)
- Testing
- 10G, 20G, 40G
- Where
- United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Clinical Nutrition Research Center, Illinois Institute of Technology
Venous Thromboembolism
The Use of Fondaparinux in Preventing Thromboembolism in High Risk Trauma Patients
Trauma patients are at high risk of developing deep vein thrombosis (DVT) and pulmonary embolism (PE). The incidence of DVT varies greatly from 5-63% among studies depending on patient's individual risk factors, modality of…
- Trial name
- NCT00531843
- Testing
- fondaparinux sodium, sequential compression devices
- Where
- United States
- Volunteers
- 105 people
- Sponsor
- Mary Knudson, M.D.
Blood Pressure, Hypertension
PACESETTER: Program to Avoid Cerebrovascular Events Through Systematic Electronic Tracking and Tailoring of an Eminent Risk-factor
Program to Avoid Cerebrovascular Events through Systematic Electronic Tracking and Tailoring of an Eminent Risk-factor (PACESETTER) aims to assess the incorporation of its stroke intervention into 2 safety net/academic health…
- Conditions
- Blood Pressure, Hypertension, Mhealth
- Trial name
- NCT03401489
- Testing
- PACESETTER
- Where
- 4 sites in United States
- Volunteers
- 120 people
- Sponsor
- Northern California Institute of Research and Education
HIV Infections, Non-Alcoholic Fatty Liver Disease
Study of Semaglutide for Non-Alcoholic Fatty Liver Disease (NAFLD), a Metabolic Syndrome With Insulin Resistance, Increased Hepatic Lipids, and Increased Cardiovascular Disease Risk (The SLIM LIVER Study)
The purpose of this study was to evaluate the effects of semaglutide on intra-hepatic triglyceride (IHTG) content in people living with HIV (PLWH), central adiposity, insulin resistance or pre-diabetes, and hepatic steatosis.
- Trial name
- NCT04216589
- Testing
- Semaglutide
- Where
- 9 sites in United States, Brazil
- Volunteers
- 51 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Multiple Myeloma
Pomalidomide in Gene Expression Profiling (GEP)-Defined High-risk Multiple Myeloma
This is a phase II study, open-label, single institution trial of pomalidomide in GEP-defined, high-risk relapsing/refractory multiple myeloma. Prior therapy must have included lenalidomide.
- Trial name
- NCT01177735
- Testing
- Pomalidomide
- Where
- United States
- Volunteers
- 71 people
- Sponsor
- University of Arkansas
Diabetes Mellitus, Type 2
BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME).
The aim of the present study is to investigate the safety of BI 10773 treatment in patients with Type 2 Diabetes Mellitus and high cardiovascular risk.
- Trial name
- NCT01131676
- Testing
- BI 10773 low dose, BI 10773 high dose
- Where
- 615 sites in United States, Argentina and 40 more
- Volunteers
- 7,064 people
- Sponsor
- Boehringer Ingelheim
Obesity
Effect of Vitamin D3 Supplementation on Insulin Resistance and Cardiovascular Risk Factors in Obese Adolescents
The prevalence of obesity has reached epidemic proportions nationally as well as internationally. Currently, 16 % of American adolescents are obese.
- Trial name
- NCT00858247
- Testing
- Vitamin D3
- Where
- United States
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Cardiovascular Disease
Prevention of Cardiovascular Disease With Med or Veg Diets
The study is a randomized, open, cross-over trial designed to test whether a vegetarian diet would benefit the cardiovascular risk profile of the participants, compared with a Mediterranean diet.
- Trial name
- CARDIVEG (NCT02641834)
- Testing
- Vegetarian diet, Mediterranean diet
- Where
- Italy
- Volunteers
- 118 people, healthy volunteers welcome
- Sponsor
- Azienda Ospedaliero-Universitaria Careggi
Diabetes, Hypertension
Multi-Targeted Cardiac Risk Intervention in Type 2 Diabetes
Our study intends to test the efficacy of pharmacist-led group interventions on a weekly basis for 4-weeks, then on a monthly basis for 5 additional months to achieve concomitant reductions in hemoglobin A1c, lipids and blood…
- Conditions
- Diabetes, Hypertension, Dyslipidemia
- Trial name
- NCT00409240
- Testing
- MEDIC
- Where
- United States
- Volunteers
- 103 people
- Sponsor
- Providence VA Medical Center
Chronic Kidney Disease, Diabetes
Improving Chronic Disease Management With Pieces
ICD-Pieces (Parkland Intelligent e-Coordination and Evaluation System) trial is a National Institutes of Health (NIH) Healthcare Systems(HCS) Collaboratory demonstration project to improve management of patients with a triad of…
- Conditions
- Chronic Kidney Disease, Diabetes, Hypertension, High BP
- Trial name
- ICD-Pieces (NCT02587936)
- Testing
- Collaborative Model of Primary care and Subspecialty care
- Where
- 4 sites in United States
- Volunteers
- 18,268 people
- Sponsor
- University of Texas Southwestern Medical Center
Cardiovascular Diseases, Coronary Artery Disease
Study On Liprimar (Atorvastatin) In Patients With Coronary Heart Disease (CHD) And High Risk Of Cardiovascular Complications
In which CHD patients with high risk of CV complications are different doses of LIPRIMAR used? For this purpose, data on hyperlipidemia will be elicited over and above the basic nosographic and demographic data, concomitant…
- Trial name
- LIGHT (NCT00993915)
- Testing
- Atorvastatin
- Volunteers
- 687 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.